PharmaLogic Holdings Corp. , a leading contract development and manufacturing organization specialized in radiopharmaceuticals, announces the completion of its previously announced acquisition of a majority stake in Agilera Pharma AS from the Institute for Energy Technology in Norway, marking a significant step forward in the company’s strategy to create the first fully-integrated, global platform specializing in radiopharmaceutical therapeutics.
Health Technology Insights: ZeOmega and MVP Health Care Partner to Advance Health Outcomes and Member Experience
The acquisition significantly enhances PharmaLogic’s capabilities across the development, manufacturing, and global distribution of commercial and clinical therapeutic radiopharmaceuticals, broadening the company’s geographic reach and operational scale.
“The addition of Agilera’s capabilities to PharmaLogic marks a key milestone in our expansion strategy into radiopharmaceutical therapeutics,” said Etienne Montagut, President and CEO of PharmaLogic. “Their proven expertise in the development and manufacturing of commercial radiopharmaceutical therapies, evidenced by successful distribution to over 30 countries, significantly enhances our end-to-end solutions. We warmly welcome the talented Agilera team and look forward to shaping the future of radiopharmaceuticals together.”
Health Technology Insights: Sun Life Launches Expert Cancer Review for Second Opinions
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
